Hypertension
📧 Sign up to get email alerts when something new happens for Hypertension.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2022-05-27FDA Approved: ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE — Supplemental Application (Taro Pharmaceuticals U.S.A., Inc.)
FDA approved a supplemental application for Enalapril Maleate and Hydrochlorothiazide (a fixed-dose combination) by Taro Pharmaceuticals U.S…
-
FDA approval · 2022-05-27FDA Approved: QUINAPRIL HCL AND HYDROCHLOROTHIAZIDE — Supplemental Application (Lupin Pharmaceuticals,Inc.)
The FDA approved Lupin Pharmaceuticals' supplemental application for Quinapril HCl and Hydrochlorothiazide, a fixed-dose combination for the…
-
CLINICAL_TRIALS trial_result · 2022-05-27Clinical Trial Update: Cardioprotective Benefits of Carvedilol-CR or Valsartan Added to Lisinopril [Phase 3]
Phase 3 trial evaluating cardioprotective benefits of adding carvedilol-CR or valsartan to lisinopril in hypertension; study completed with …
-
FDA approval · 2022-05-26FDA Approved: QUINAPRIL HYDROCHLORIDE/HYDROCHLOROTHIAZIDE — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for Quinapril hydrochloride/hydrochlorothiazide from Aurobindo Pharma Limited, enabling the mark…
-
FDA approval · 2022-05-25FDA Approved: QUINAPRIL AND HYDROCHLOROTHIAZIDE 10/12.5 — Supplemental Application (Cipla USA Inc.)
The FDA approved Cipla USA Inc.'s supplemental application for Quinapril and Hydrochlorothiazide in strengths 10/12.5, 20/12.5, and 20/25.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA withdrawal · 2022-05-20EMA Withdrawn: Rasilez HCT (aliskiren;hydrochlorothiazide) — Noden Pharma DAC
The EMA has withdrawn Rasilez HCT (aliskiren; hydrochlorothiazide) from the market.
-
CLINICAL_TRIALS trial_result · 2022-05-20Clinical Trial Update: Online Trial Examining Validity and Reliability of the Shared Decision Making Process Survey
A completed clinical trial evaluating the validity and reliability of the Shared Decision Making Process Survey, sponsored by Massachusetts …
-
CLINICAL_TRIALS trial_result · 2022-05-10Clinical Trial Update: Evaluate Efficacy and Safety of Ezetimibe/Rosuvastatin and Candesartan Cilexetil/Amlodipine Besylate Combination Tablets [Phase 4]
Phase 4 trial update evaluating the efficacy and safety of fixed-dose combination tablets containing ezetimibe/rosuvastatin and candesartan …
-
CLINICAL_TRIALS trial_result · 2022-05-10Clinical Trial Update: Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS) [Phase 2]
Phase 2 trial investigating chloroquine for metabolic syndrome conditions has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2022-05-09Clinical Trial Update: Preventing Sickle Cell Kidney Disease [Phase 2]
Phase 2 clinical trial update on preventing sickle cell kidney disease; status terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2022-05-06Clinical Trial Update: The Efficacy of Dietary Flaxseed for the Reduction of Blood Pressure in Newly Diagnosed Hypertensive Individuals [Phase 2, Phase 3]
Trial update on dietary flaxseed for reducing blood pressure in newly diagnosed hypertension; study terminated after Phase 2/3.
-
FDA approval · 2022-05-05FDA Approved: DILTIAZEM HYDROCHLORIDE EXTENDED-RELEASE — Original Application (Dr. Reddy's Labratories Inc.)
FDA approves Dr. Reddy's Laboratories' generic diltiazem hydrochloride extended-release tablet (ANDA 215775).
-
CLINICAL_TRIALS trial_result · 2022-04-29Clinical Trial Update: Nifedipine GITS and Amlodipine Besylate on Recovery of Blood Pressure Rhythm and Arterial Stiffness [Phase 4]
Phase 4 trial update on nifedipine GITS and amlodipine besylate for recovery of blood pressure rhythm and arterial stiffness in hypertension…
-
FDA approval · 2022-04-26FDA Approved: NIFEDIPINE — Supplemental Application (Ascend Laboratories, LLC)
The FDA approved a supplemental application for nifedipine from Ascend Laboratories, LLC, under the existing ANDA, authorizing changes to an…
-
CLINICAL_TRIALS trial_result · 2022-04-25Clinical Trial Update: Comparison of Pharmacodynamic Effects of Sotagliflozin and Empagliflozin in T2DM Patients With Mild to Moderate Hypertension [Phase 2]
Phase 2 trial comparing pharmacodynamic effects of sotagliflozin vs empagliflozin in type 2 diabetes patients with mild to moderate hyperten…
-
CLINICAL_TRIALS trial_result · 2022-04-15Clinical Trial Update: The Smart Hypertension Control Study [NA]
A completed clinical trial on hypertension control sponsored by Northwestern University, with results posted in 2022.
-
FDA approval · 2022-04-12FDA Approved: FUROSEMIDE — Supplemental Application (Phlow Corporation)
FDA granted a supplemental approval for Furosemide by Phlow Corporation under the existing NDA; the snippet does not specify the exact natur…
-
FDA approval · 2022-04-07FDA Approved: NEBIVOLOL — Original Application (Solco Healthcare US, LLC)
The FDA approved the original application for Nebivolol (generic) from Solco Healthcare US, LLC. Nebivolol is used to treat hypertension.
-
FDA approval · 2022-04-05FDA Approved: IRBESARTAN AND HYDROCHLOROTHIAZIDE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for the irbesartan and hydrochlorothiazide product from Hikma Pharmaceuticals USA, updating labeling…
-
FDA approval · 2022-04-05FDA Approved: IRBESARTAN AND HYDROCHLOROTHIAZIDE — Supplemental Application (Macleods Pharmaceuticals Limited)
FDA approved a supplemental application for Macleods' irbesartan/hydrochlorothiazide combination tablet, expanding its labeling for the trea…
-
FDA approval · 2022-04-04FDA Approved: VALSARTAN AND HYDROCHLOROTHIAZIDE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for a generic fixed-dose combination of valsartan and hydrochlorothiazide by Aurobindo Pharma Limite…
-
CLINICAL_TRIALS trial_result · 2022-03-31Clinical Trial Update: Chlorthalidone in Chronic Kidney Disease [Phase 2]
Phase 2 trial update for chlorthalidone in chronic kidney disease has been completed with results posted.
-
FDA approval · 2022-03-31FDA Approved: QUINAPRIL — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for a quinapril hydrochloride generic product manufactured by Aurobindo Pharma Limited.
-
FDA approval · 2022-03-30FDA Approved: ENALAPRIL MALEATE ORAL SOLUTION — Original Application (Ascend Laboratories, LLC)
The FDA approved Ascend Laboratories' enalapril maleate oral solution as an original generic application for enalapril; the drug is used to …
-
FDA approval · 2022-03-29FDA Approved: NIFEDIPINE — Original Application (Ascend Laboratories, LLC)
FDA approved Ascend Laboratories' Original Application for nifedipine, a calcium channel blocker used to treat hypertension and angina.